TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32341140

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in HFrEF patients
Number of subjects: 5414

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in HFmrEF patients
Number of subjects: 5414

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in HFpEF patients
Number of subjects: 5414
Study: 32341321

Group type: EXPERIMENTAL
Intervention: First-operated eye
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fellow-operated eye
Number of subjects: 74
Study: 32341578

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 PD-1-edited T cells
Number of subjects: 22
Study: 32341691

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 32342016

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) combined with music therapy (10 therapy sessions and related homework)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 43
Study: 32342831

Group type: EXPERIMENTAL
Intervention: Dabigatran treatment initiated within 14 days of TIA/minor stroke
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dabigatran treatment
Number of subjects: 101
Study: 32342838

Group type: EXPERIMENTAL
Intervention: Dengue surveillance system
Number of subjects: 0
Study: 32343050

Group type: EXPERIMENTAL
Intervention: Electronic retinal implant (Retina Implant Alpha AMS) with intensive visual training
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Electronic retinal implant (Retina Implant Alpha AMS)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intensive visual training
Number of subjects: 1
Study: 32343196

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32343248

Group type: EXPERIMENTAL
Intervention: Digital health tools including discharge video and checklist
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Postdischarge messaging service
Number of subjects: 510
Study: 32343251

Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Including specific cadence bands and peak cadences
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Children meeting the WHO recommendation of 60 minutes per day of MVPA
Number of subjects: 105
Study: 32343312

Group type: EXPERIMENTAL
Intervention: Cold exposure in BATpos individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold exposure in BATneg individuals
Number of subjects: 0
Study: 32343640

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg plus Nivolumab 3 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regorafenib 80 mg plus Nivolumab 3 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regorafenib 120 mg plus Nivolumab 3 mg/kg
Number of subjects: 50
Study: 32343796

Group type: EXPERIMENTAL
Intervention: Haploidentical bone marrow transplantation (BMT) with intensive graft-versus-host disease (GVHD) prophylaxis including posttransplantation cyclophosphamide.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Haploidentical BMT with posttransplant cyclophosphamide
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Haploidentical BMT with 400 cGy total body irradiation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Haploidentical BMT with increased total body irradiation dose to 400 cGy
Number of subjects: 74
Study: 32344248

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 255
Study: 32344296

Group type: EXPERIMENTAL
Intervention: Weight loss (±5% between diagnosis and post-treatment)
Number of subjects: 993

Group type: COMPARATOR
Intervention: Weight gain or stability
Number of subjects: 993
Study: 32345039

Group type: EXPERIMENTAL
Intervention: Resting distal-to-aortic coronary pressure ratio (Pd/Pa) ≤0.92
Number of subjects: 4707

Group type: COMPARATOR
Intervention: Hyperemic fractional flow reserve (FFR) ≤0.80
Number of subjects: 4707
Study: 32345071

Group type: EXPERIMENTAL
Intervention: Psychological factors assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary capacity assessment
Number of subjects: 0
Study: 32345378

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg (UK subgroup)
Number of subjects: 506
Study: 32345417

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 50
Study: 32346071

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/smq on days 1, 8, 15 every 4 weeks up to six cycles, progressive disease or intolerable toxicity
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 68
Study: 32346484

Group type: EXPERIMENTAL
Intervention: Home-based prehabilitation exercise intervention (increasing daily step-count during and after NAC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home-based prehabilitation exercise intervention
Number of subjects: 40
Study: 32346485

Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health intervention program including training teachers, drama skit, menstrual kit training, pain relief guidance, and WASH improvements.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Comprehensive menstrual health intervention program
Number of subjects: 450
Study: 32346486

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 82
Study: 32346907

Group type: EXPERIMENTAL
Intervention: TST (Total Sleep Time)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AAC (Activity during Sleep)
Number of subjects: 22
Study: 32347439

Group type: EXPERIMENTAL
Intervention: Effective contraception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for symptomatic children under five
Number of subjects: 0
Study: 32347554

Group type: EXPERIMENTAL
Intervention: Bedside handover
Number of subjects: 774

Group type: COMPARATOR
Intervention: Traditional handover
Number of subjects: 774
Study: 32347804

Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Self-monitoring smartphone app and coaching calls
Number of subjects: 9
Study: 32347917

Group type: EXPERIMENTAL
Intervention: Spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) imaging
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Presence of autofluorescence
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Foveal hypoplasia
Number of subjects: 26
Study: 32347984

Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 1984

Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 1984
Study: 32348254

Group type: EXPERIMENTAL
Intervention: CardioTracker (CART)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pulse oximeter
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (healthy subjects with sinus rhythm)
Number of subjects: 100
Study: 32348267

Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule (CCR) implementation
Number of subjects: 300000

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 300000
Study: 32348281

Group type: EXPERIMENTAL
Intervention: GetActive
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit
Number of subjects: 82

Group type: COMPARATOR
Intervention: GetActive and GetActive-Fitbit
Number of subjects: 82
Study: 32348286

Group type: EXPERIMENTAL
Intervention: EX-HD (digital smoking cessation program with additional content specific to heavy drinking)
Number of subjects: 83

Group type: COMPARATOR
Intervention: EX-S (standard digital smoking cessation program)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: EX-HD and EX-S (both conditions)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: EX-HD
Number of subjects: 83
Study: 32348346

Group type: EXPERIMENTAL
Intervention: 60 Hz STN DBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 140 Hz STN DBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Turning and barrier course (TBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 0
Study: 32348643

Group type: EXPERIMENTAL
Intervention: Mental disorders
Number of subjects: 5940299

Group type: EXPERIMENTAL
Intervention: Eating disorders
Number of subjects: 5940299

Group type: EXPERIMENTAL
Intervention: Organic mental disorders
Number of subjects: 5940299

Group type: EXPERIMENTAL
Intervention: Developmental disorder
Number of subjects: 5940299

Group type: EXPERIMENTAL
Intervention: Organic mental disorder
Number of subjects: 5940299

Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 5940299
Study: 32349020

Group type: EXPERIMENTAL
Intervention: Heterogeneous dose-escalated prostate stereotactic body radiation therapy (target volume received 36.25 Gy/5 fx; target >3 mm from sensitive structures escalated to 50 Gy/5 fx)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Heterogeneous dose-escalated prostate stereotactic body radiation therapy
Number of subjects: 35
Study: 32349119

Group type: EXPERIMENTAL
Intervention: Escitalopram (8 weeks of open-label treatment)
Number of subjects: 87
Study: 32349629

Group type: EXPERIMENTAL
Intervention: Resistance training with blood flow restriction for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32349790

Group type: EXPERIMENTAL
Intervention: iCOPE (interactive computer- and text message-delivered personalized feedback intervention with distress tolerance skills training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 32349803

Group type: EXPERIMENTAL
Intervention: ASD youths
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Unaffected siblings of ASD youths
Number of subjects: 240

Group type: COMPARATOR
Intervention: TDC youths
Number of subjects: 240
Study: 32350018

Group type: EXPERIMENTAL
Intervention: End-of-life care protocol implementation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Retrospective chart reviews
Number of subjects: 140

Group type: COMPARATOR
Intervention: Pilot phase to validate CODE questionnaire
Number of subjects: 140

Group type: COMPARATOR
Intervention: Focus group discussions (FGDs)
Number of subjects: 140
Study: 32350119

Group type: EXPERIMENTAL
Intervention: One vaccine with peptides in pICLC+IFA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SSV with peptides+IFA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vaccines containing pICLC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SSV with peptides in IFA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SSV with IFA and peptides
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Skin injected with IFA without peptides
Number of subjects: 27
Study: 32350338

Group type: EXPERIMENTAL
Intervention: Dysphagia Severity Rating Scale (DSRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharyngeal electrical stimulation
Number of subjects: 0
Study: 32350529

Group type: EXPERIMENTAL
Intervention: Empiric treatment (antibiotics and/or antifungals)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Inappropriate prescriptions
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Laboratory-diagnosed cause of vaginitis
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: No BV, TV, or VVC
Number of subjects: 303
Study: 32350679

Group type: EXPERIMENTAL
Intervention: Breast Conservation Therapy (BCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mastectomy with Reconstruction (M + R)
Number of subjects: 0
Study: 32350901

Group type: EXPERIMENTAL
Intervention: Helium plasma device
Number of subjects: 55
Study: 32350915

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 14980

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 14980

Group type: EXPERIMENTAL
Intervention: All-cause death, cardiac death, myocardial infarction, stroke or systemic embolic event, major bleeding
Number of subjects: 14980
Study: 32351419

Group type: EXPERIMENTAL
Intervention: Proxy version of the WHODAS 2.0
Number of subjects: 77

Group type: COMPARATOR
Intervention: Outpatients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Drug-induced parkinsonism
Number of subjects: 77
Study: 32351609

Group type: EXPERIMENTAL
Intervention: Jueyin Granules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32351966

Group type: EXPERIMENTAL
Intervention: Coconut oil and caprylic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coconut oil and caprylic acid with glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without coconut oil and caprylic acid)
Number of subjects: 0
Study: 32352498

Group type: EXPERIMENTAL
Intervention: Nivolumab, 240 mg intravenously every 2 weeks for 16 weeks, then 480 mg every 4 weeks until disease progression or unacceptable toxic effects.
Number of subjects: 54
Study: 32352564

Group type: EXPERIMENTAL
Intervention: Oscillating devices (e.g., high frequency chest wall oscillation)
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Oscillating devices
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Other forms of physiotherapy (e.g., positive expiratory pressure)
Number of subjects: 1114
Study: 32352586

Group type: EXPERIMENTAL
Intervention: Digital medicine programme (DMP)
Number of subjects: 288
Study: 32352653

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 794

Group type: COMPARATOR
Intervention: Postmarketing data
Number of subjects: 794
Study: 32353036

Group type: EXPERIMENTAL
Intervention: Expert mothers (N=37)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Non-expert mothers (N=100)
Number of subjects: 137
Study: 32353110

Group type: EXPERIMENTAL
Intervention: Anticancer drugs (19 identified drugs including lenalidomide, pomalidomide, nilotinib, ponatinib, midostaurin, azacytidine, clofarabine, docetaxel, obinutuzumab)
Number of subjects: 11757
Study: 32353318

Group type: EXPERIMENTAL
Intervention: Open fractures
Number of subjects: 31255

Group type: EXPERIMENTAL
Intervention: Closed fractures
Number of subjects: 31255

Group type: EXPERIMENTAL
Intervention: Reasons for delays
Number of subjects: 31255

Group type: EXPERIMENTAL
Intervention: Transportation method
Number of subjects: 31255

Group type: EXPERIMENTAL
Intervention: Fracture type
Number of subjects: 31255
Study: 32353599

Group type: EXPERIMENTAL
Intervention: Dako PD-L1 IHC 73-10 assay
Number of subjects: 231

Group type: COMPARATOR
Intervention: Dako PD-L1 IHC 22C3 assay
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1)
Number of subjects: 231
Study: 32354451

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD) eligibility assessment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Right-sided S-ICD screening
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Left-sided S-ICD screening
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Machine learning prediction of S-ICD eligibility
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Comparison of S-ICD eligibility by gender
Number of subjects: 101
Study: 32354696

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for severe sepsis prediction
Number of subjects: 17758
Study: 32354716

Group type: EXPERIMENTAL
Intervention: Semiautomated 2D measurements
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volumetric measurements
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual 2D cross-product measurements
Number of subjects: 10
Study: 32354780

Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 32355442

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with Oculofolin containing 900 µg L-methylfolate for three months
Number of subjects: 24
Study: 32355493

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg every 2 weeks)
Number of subjects: 1
Study: 32355503

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of alum-adjuvanted recombinant HBV vaccine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of alum-adjuvanted recombinant HBV vaccine
Number of subjects: 52
Study: 32355632

Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical management (NSM)
Number of subjects: 0
Study: 32355775

Group type: EXPERIMENTAL
Intervention: Severe WMHs (grades 5-6)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Moderate WMHs (grades 3-4)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Periventricular WMHs (PVWMHs)
Number of subjects: 787

Group type: COMPARATOR
Intervention: 3-month functional outcome
Number of subjects: 787

Group type: COMPARATOR
Intervention: Stroke recurrence
Number of subjects: 787

Group type: COMPARATOR
Intervention: Antiplatelet therapy
Number of subjects: 787
Study: 32355819

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF) + MCAO
Number of subjects: 0

Group type: COMPARATOR
Intervention: MCAO
Number of subjects: 0
Study: 32355836

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily
Number of subjects: 280

Group type: COMPARATOR
Intervention: Warfarin (VKA) with targeted INR 2-2.5
Number of subjects: 280
Study: 32356159

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) of benign breast lesions (BBLs)
Number of subjects: 440
Study: 32356774

Group type: EXPERIMENTAL
Intervention: This is Quitting (text message quit vaping program)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 2600
Study: 32357207

Group type: EXPERIMENTAL
Intervention: Baseline BNP measurement
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Baseline BNP and ST2 measurement
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Time-varying BNP measurement at 3-month intervals
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Time-varying ST2 measurement at 3-month intervals
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: C-reactive protein, ESR, and TNF-α measurements
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Repeated laboratory measurements over a year
Number of subjects: 196
Study: 32357901

Group type: EXPERIMENTAL
Intervention: Women on long-term ART
Number of subjects: 30

Group type: COMPARATOR
Intervention: Men on long-term ART
Number of subjects: 30
Study: 32357963

Group type: EXPERIMENTAL
Intervention: MTL-CEBPA (28-160 mg/m) administered intravenously once a week for 3 weeks followed by a rest period of 1 week per treatment cycle
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MTL-CEBPA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MTL-CEBPA + sorafenib
Number of subjects: 38
Study: 32358359

Group type: EXPERIMENTAL
Intervention: Suprarenal fixation (SR) during EVAR
Number of subjects: 0
Study: 32358769

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation Therapy plus treatment-as-usual (VNS + TAU)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 156
Study: 32358807

Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control (very low dose of mannitol or non-respirable mannitol)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Mannitol plus dornase alfa
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Mannitol alone
Number of subjects: 784

Group type: COMPARATOR
Intervention: Dornase alfa alone
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 784
Study: 32358837

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Heparin plus aspirin
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: LMWH plus aspirin
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: UFH plus aspirin
Number of subjects: 1672
Study: 32358887

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Activity Measure for Post-Acute Care basic mobility
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Motricity Index
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Functional Independence Measure mobility subscale
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Trunk Control Test
Number of subjects: 105

Group type: COMPARATOR
Intervention: Gait speed, Functional Reach Test, 6-minute Walk Test, Timed Up and Go
Number of subjects: 105
Study: 32358998

Group type: EXPERIMENTAL
Intervention: ELF score (≥11.1)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: ELF score (<10.1)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: ELF score
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: HA alone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: ELF score in strictly compensated ACLD (cACLD) patients
Number of subjects: 201
Study: 32359091

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every three weeks (KEYNOTE-158)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every two weeks (KEYNOTE-028)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 128
Study: 32359149

Group type: EXPERIMENTAL
Intervention: Type I Interferon (IFN-α) treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: C-reactive protein
Number of subjects: 101
Study: 32359358

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 5625

Group type: EXPERIMENTAL
Intervention: Heart failure with reduced ejection fraction (HFrEF) with DM
Number of subjects: 5625

Group type: EXPERIMENTAL
Intervention: Inadequate glycemic control (HbA1c ≥ 7.0%)
Number of subjects: 5625

Group type: COMPARATOR
Intervention: Adequate glycemic control (HbA1c < 7.0%)
Number of subjects: 5625

Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 5625

Group type: COMPARATOR
Intervention: In-hospital mortality
Number of subjects: 5625
Study: 32359360

Group type: EXPERIMENTAL
Intervention: Novel PET tracer for COX-2 measurement
Number of subjects: 0
Study: 32359490

Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice daily)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 32359671

Group type: EXPERIMENTAL
Intervention: Civil commitment for psychiatric disorders
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Civil commitment for drug misuse
Number of subjects: 254
Study: 32359748

Group type: EXPERIMENTAL
Intervention: Fibroscan® (XL probe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histological examination (liver biopsy)
Number of subjects: 0